Visual and auditory hallucinations with excessive intake of paroxetine
Department of Psychiatry, Juntendo University, Edo, Tōkyō, JapanPsychiatry and Clinical Neurosciences (Impact Factor: 1.63). 11/2003; 57(5):548-9. DOI: 10.1046/j.1440-1819.2003.01163.x
Full-text previewDOI: · Available from: onlinelibrary.wiley.com
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.
- [Show abstract] [Hide abstract]
ABSTRACT: Published case reports on complex visual hallucinations (CVH) occurring during antidepressant (AD) treatment were reviewed. Thirteen cases of CVH associated with SSRI treatment, 16 cases during tricyclic drug treatment and seven cases with other AD drug treatments were found. Nine patients were taking concomitant drugs while on therapy with SSRIs and four had a neurological disease in addition to depression. The cholinergic impoverishment occurring in dementia states or during concomitant therapy with anticholinergic drugs could increase the sensitivity to serotonergic agonists, triggering the manifestation of CVH. During tricyclic drug treatment, half of the reports were of hypnopompic or hypnagogic hallucinations and this can be associated with the effects of tricyclics (TCA) on sleep architecture. It is likely that the potent anticholinergic effect of amitriptyline was potentiated in a situation of a rapidly changing state of consciousness. In general, the review supports the view that an imbalance between serotonin and acetylcholine systems is at the root of AD-induced CVH, with a profile defined by a cholinergic hypoactivity and a serotonergic hyperactivity. Caution is needed when administering a combination of serotonergic and anticholinergic AD in the treatment of the demented population and in other already compromised patients because there is a risk of precipitating CVH. CopyrightHuman Psychopharmacology Clinical and Experimental 12/2004; 19(8):577-84. DOI:10.1002/hup.640 · 2.19 Impact Factor
- Revista de neurologia 12/2004; 39(11):1092. · 0.83 Impact Factor
- Revista de neurologia 03/2006; 42(5):315-7. · 0.83 Impact Factor